Trabectedin No Better Than Physician’s Choice in Recurrent Ovarian Cancer
There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.
Ovarian Cancer
Maintenance Rucaparib May Improve Outcomes in Ovarian Cancer
Investigator analysis showed that PFS was improved in the intent-to-treat population with rucaparib, as well as in the HRD population.
Adding Relacorilant to Nab-Paclitaxel May Benefit Some Patients With Ovarian Cancer
Combining relacorilant with nab-paclitaxel improved overall survival in a subset of patients with recurrent, platinum-resistant ovarian cancer.
Appearance of Ovarian Lesions on Ultrasound May Predict Malignancy
The malignancy rate was less than 1% for classic lesions and 32% for nonclassic lesions with blood flow.
Cancer Researchers Aren’t Reporting Quality of Life Outcomes Accurately
Quality of life outcomes were reported favorably for trials that showed no improvement in quality of life.
Ovarian Cancer Is Not a Silent Killer
Barbara Goff, MD, discusses ovarian cancer and how recognizing symptoms can lead to early detection and reduce misdiagnosis.
BRCA1/2 Variants Associated With More Cancers Than Previously Thought
Researchers identified associations between pathogenic variants in BRCA1/2 and 7 cancers.
Fuzuloparib Maintenance Prolongs PFS in Recurrent Ovarian Cancer
Fuzuloparib maintenance significantly delayed the time to disease progression and time to subsequent chemotherapy.
Rucaparib Prolongs PFS in BRCA-Mutated, Relapsed Ovarian Cancer
The median duration of response was significantly longer with rucaparib than with standard chemotherapy.
Olaparib Alone, in Combination Does Not Improve PFS in Platinum-Sensitive Ovarian Cancer
Despite the lack of improvement in the overall cohort, olaparib monotherapy and olaparib-cediranib did exhibit activity in a subset of patients with a germline BRCA mutation.
- Loading...
Loading...
Next post in Gynecologic Cancer
Loading... 
Loading...